利润分配预案公告 证券代码：300653 证券简称：正海生物 公告编号：2025-010 烟台正海生物科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 公司拟以 2024 年 12 月 31 日总股本 180,000,000 股剔除股份回购专户持有的 2,360,050 股后的 177,639,950 股为基数，向全体股东每 10 股派发现金红利人民 币 4.60 元（含税），共派发现金红利人民币 81,714,377.00 元（含税）。本年度公 司不以资本公积金转增股本，不送红股。 一、审议程序 烟台正海生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 12 日 召开第四届董事会 2025 年第一次独立董事专门会议、第四届董事会第六次会议、 第四届监事会第五次会议，审议通过了《关于公司 2024 年度利润分配预案的议 案》。 本议案尚需提交公司 2024 年度股东大会审议。 二、利润分配方案的基本情况 经天职国际会计师事务所（特殊普通合伙）审计，2024 年度，公司实现归 属 ...

Revenue and Financial Performance - The company's operating revenue for 2024 was ¥363,225,351.49, a decrease of 12.19% compared to ¥413,652,710.67 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥134,639,109.00, down 29.49% from ¥190,957,573.45 in 2023[24]. - The basic earnings per share for 2024 was ¥0.75, reflecting a decline of 29.25% from ¥1.06 in 2023[24]. - The total assets at the end of 2024 amounted to ¥980,113,621.99, a decrease of 6.99% from ¥1,053,824,628.67 at the end of 2023[24]. - The company reported a cash flow from operating activities of ¥151,383,955.72 in 2024, which is a 16.12% decrease from ¥180,477,813.36 in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥113,203,783.85, down 32.59% from ¥167,926,863.25 in 2023[24]. - The company achieved operating revenue of 363.23 million yuan, a decrease of 12.19% compared to the same period last year[52]. - The net profit attributable to shareholders was 134.64 million yuan, down 29.49% year-on-year[52]. - The gross profit margin for the medical device sector was 87.64%, down 2.26% from the previous year, with operating costs increasing by 7.45% to ¥44,885,424.69[72]. - The company achieved a net increase in cash and cash equivalents of ¥53,112,660.09, a significant increase of 3391.62% compared to ¥1,521,145.11 in the previous year[68]. - The cash flow from investment activities showed a significant change, with a net inflow of ¥95,662,520.05 compared to a net outflow of ¥70,951,531.21 in the previous year, marking a 234.83% change[68]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 25%[129]. - The company has set a future outlook with a revenue guidance of 1.8 billion yuan for the next quarter, indicating a projected growth of 20%[131]. Product Development and Innovation - The company is developing a pipeline of new products including calcium silicate bioceramic bone repair materials, cavity repair membranes, breast patches, and human umbilical cord mesenchymal stem cells[4]. - The company aims to innovate and develop regenerative medical products to meet clinical needs, focusing on high-value medical consumables[34]. - The company is actively developing new products, including oral repair membranes and hard brain (spinal) membrane patches, with ongoing research and development efforts[111]. - The company is in the registration phase for new products, including calcium silicate bio-ceramic bone repair materials and non-absorbable surgical sutures[80]. - The company’s new oral repair membrane received the medical device registration certificate in January 2025, expanding its product matrix[55]. - The calcium silicate bio-ceramic bone repair material is in the registration stage and is the first of its kind in the domestic market[56]. - The company is advancing clinical trials for the uterine repair membrane and breast patch, with the latter showing promising results in clinical trials[56]. - The company is committed to the field of regenerative medicine, focusing on core technology and expanding innovative business areas in response to industry challenges[46]. - The company is enhancing its quality management system to ensure the safety and effectiveness of its implantable medical devices[110]. Market and Competitive Landscape - The global medical device market is projected to grow from $546.5 billion in 2021 to $753.8 billion by 2028, with a compound annual growth rate of 4.7%[37]. - The overall revenue of China's medical device industry reached CNY 1,310 billion in 2023, with a compound annual growth rate of 10% from 2014 to 2023[40]. - The number of medical device manufacturing enterprises in China increased by 6.23% from 32,848 at the end of 2023 to 34,894 by December 2024[40]. - The number of approved registrations for Class III medical devices in China grew by 27.72% year-on-year, totaling 2,655 items in 2024[40]. - The high-value medical consumables centralized procurement has entered a new phase of normalization and institutionalization, with plans for the sixth batch of procurement in the second half of 2025[41]. - The company successfully won bids for absorbable dura mater and dura mater patch products in multiple provinces, indicating strong market positioning[42][43]. - The company has developed a range of high-quality clinical consumables, including absorbable dura mater patches and active biological bone products, establishing a strong market presence[46]. - The company has established a clear market expansion strategy, focusing on the dental implant sector and enhancing sales performance in this area[112]. - The company is facing challenges due to centralized procurement policies affecting its membrane products, which may impact future revenue[112]. Research and Development - The company aims to enhance its R&D capabilities and product development to mitigate growth risks and improve operational efficiency[5]. - The company has a robust pipeline of products under research, although the time to market and revenue generation for new products may involve uncertainties[4]. - The company emphasizes the importance of integrating resources to accelerate the transformation of new technologies and expand its product matrix[5]. - The company has established a stable and efficient R&D team with expertise in clinical medicine, pharmaceuticals, and tissue engineering, supporting continuous technological innovation[61]. - The number of R&D personnel increased by 61.02% to 95 in 2024 from 59 in 2023, representing 25.33% of the total workforce[80]. - R&D investment amounted to ¥39,521,831.02 in 2024, accounting for 10.88% of operating revenue[81]. - Research and development expenses decreased by 10.28% to ¥39,521,831.02, attributed to fewer projects entering the clinical trial phase compared to the previous year[68]. Corporate Governance and Management - The governance structure of the company is robust, with a clear separation of powers among the shareholders, board of directors, and management, ensuring compliance with regulatory requirements[115]. - The company has maintained independence from its controlling shareholders, with no instances of fund occupation or guarantees provided to related parties during the reporting period[116]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory standards[116]. - The company has implemented a performance evaluation system for senior management, ensuring that the evaluation standards and incentive mechanisms are transparent and comply with legal regulations[118]. - The company strictly adheres to information disclosure requirements, ensuring that all shareholders have equal access to information through designated newspapers and websites[119]. - The company has established a transparent and effective incentive mechanism for senior management, which is regularly reviewed and updated[118]. - The company has a clear strategy for maintaining independence and ensuring compliance with corporate governance standards[120]. - The company announced a board restructuring on April 22, 2024, with several new appointments including Guo Huanxiang as Chairman and Qun Dong as Vice Chairman[126]. - The company reported a change in management with Song Kan appointed as General Manager and Zhao Li as Deputy General Manager on April 26, 2024[126]. Environmental and Social Responsibility - The company actively responded to national green development initiatives by enhancing its environmental management system and optimizing resource management[166]. - The company has implemented various environmental protection measures, including the installation of activated carbon adsorption boxes and low-nitrogen combustion technology[167]. - Wastewater from production processes is treated through multiple stages before being discharged into the municipal sewage system[167]. - The company has achieved certifications for ISO14001, ISO50001, and ISO45001, demonstrating its commitment to environmental management and sustainability[166]. - The company ensures that all construction projects comply with environmental regulations and have received local environmental protection department approvals[167]. - The company has been recognized as a green factory by Shandong Province, following its previous designation as a municipal green factory in 2023, reflecting its commitment to sustainable development[168]. - The company conducts quarterly inspections of its wastewater discharge by qualified third-party agencies, with no environmental violations reported during the reporting period[168]. - The company is committed to maintaining a green, low-carbon, and sustainable development path, as evidenced by its recent accolades in environmental performance[168]. Future Outlook and Strategic Initiatives - The company plans to distribute a cash dividend of 4.60 RMB per 10 shares (including tax) based on a total share capital of 177,639,950 shares as of December 31, 2024[8]. - The company plans to enhance market competitiveness through a "precision marketing" strategy by 2025, focusing on clinical needs and feedback mechanisms[101]. - The company is expected to continue its market expansion and product development strategies, although specific figures and timelines were not provided in the current documents[126]. - The company has initiated a share repurchase program, with the first announcement made on April 4, 2024[200]. - The company has announced a shareholder dividend return plan for the next three years (2024-2026)[200].

烟 台 正 海生 物 科技 股 份 有限 公 司 内 部 控 制审 计 报告 天职业字[2025]14478 号 目 录 内 部 控 制 审 计 报 告 1 1 内部控制审计报告 天职业字[2025]14478 号 烟台正海生物科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了烟台正海生物科 技股份有限公司（以下简称"正海生物"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的规定，建立 健全和有效实施内部控制，并评价其有效性是正海生物公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并对注意到的 非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化可能导致内部 控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的有效 性具有一定风险。 四、财务报 ...

烟 台 正 海生 物 科技 股 份 有限 公 司 2024 年 度 控股 股东 及 其 他关 联 方 资 金 占 用情 况 的专 项 说 明 天职业字[2025]14474 号 目 录 2024 年度控股股东及其他关联方资金占用情况的专项说明 1 2024 年度非经营性资金占用及其他关联资金往来情况汇总表 2 我们审计了烟台正海生物科技股份有限公司（以下简称"正海生物公司"）财务报表，包括 2024年12月31日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公司 现金流量表、合并及母公司股东权益变动表以及财务报表附注，并于2025年4月13日签署了无 保留意见的审计报告。 根据中国证监会、公安部、国资委、中国银保监会《上市公司监管指引第8号——上市公司 资金往来、对外担保的监管要求》和证券交易所相关文件要求，正海生物公司编制了后附的2024 年度非经营性资金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制和对外披露汇总表，并确保其真实性、合法性及完整性是正海生物公司管理层的责任。 我们的责任是对汇总表所载信息与已审计财务报表进行复核。经复核，我们认为，正海生物公 司汇总表在 ...

独立董事述职报告 烟台正海生物科技股份有限公司 2024 年度独立董事述职报告 本人作为烟台正海生物科技股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《公司 章程》等相关法律法规和规章制度的规定和要求，本着客观、公正、独立的原则， 忠实、勤勉、尽责地履行职务，积极发挥独立董事作用，切实履行了独立董事的 责任与义务。在 2024 年的工作中，本人积极出席相关会议，慎重审议董事会和 董事会专门委员会的各项议案，发挥了独立董事的独立性和专业性作用，维护了 公司和股东尤其是中小股东的利益。 现将 2024 年度本人履行独立董事职责的工作情况报告如下： 一、独立董事基本情况 本人王辉，1964 年 5 月出生，中国国籍,无境外居留权,硕士研究生学历。曾 任山东省畜产进出口公司财务科副科长，青岛中土畜华林进出口有限公司财务总 监,青岛东软电脑技术有限公司副总经理，青岛东软载波科技股份有限公司副总 经理、董事会秘书；现任上海锦岳私募管理有限公司董事、烟台正海生物科技股 份有限公司 ...

独立董事述职报告 烟台正海生物科技股份有限公司 2024 年度独立董事述职报告 本人作为烟台正海生物科技股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《公司 章程》等相关法律法规和规章制度的规定和要求，本着客观、公正、独立的原则， 忠实、勤勉、尽责地履行职务，积极发挥独立董事作用，切实履行了独立董事的 责任与义务。在 2024 年的工作中，本人积极出席相关会议，慎重审议董事会和 董事会专门委员会的各项议案，发挥了独立董事的独立性和专业性作用，维护了 公司和股东尤其是中小股东的利益。 现将 2024 年度本人履行独立董事职责的工作情况报告如下： 一、独立董事基本情况 本人李江华，1966 年出生,中国国籍,无永久境外居留权,江南大学发酵工程工 学博士学位，2012 年起任江南大学生物工程学院教授、博士生导师，现任浙江远 江生物科技有限公司副董事长、嘉兴未来食品研究院常务副院长、中国食品科技 学会有机酸分会理事、烟台正海生物科技股份有限公司独立董事。长期从事发酵 工程和 ...

独立董事述职报告 一、独立董事基本情况 本人许卉，1971 年出生，中国国籍，无永久境外居留权，上海中医药大学中 药学博士学位，现任烟台大学药学院教授，博士研究生导师，中国医药生物技术 协会药物分析技术分会第二届委员会委员，曾任烟台正海生物科技股份有限公司 第三届董事会独立董事。 本人在担任公司独立董事期间，未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在妨碍本 人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公 司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律、法规、规范性文件中关于独立董事独立性的相 关要求。 二、独立董事年度履职情况 （一）出席会议情况 2024 年，公司共召开 6 次董事会和 2 次股东大会。在本人担任第三届独立 董事任期届满前，公司召开了 1 次董事会和 1 次股东大会，本人亲自出席 1 次 董事会及 1 次股东大会。会议召开前我认真阅读公司提供的相关材料，研究决策 事项，了解公司经营和运作情况，为参与公司重要决策做好充分准备。参加的各 项会议的召集召开 ...

独立董事述职报告 烟台正海生物科技股份有限公司 2024 年度独立董事述职报告 1 独立董事述职报告 本人作为烟台正海生物科技股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《公司 章程》等相关法律法规和规章制度的规定和要求，本着客观、公正、独立的原则， 忠实、勤勉、尽责地履行职务，积极发挥独立董事作用，切实履行了独立董事的 责任与义务。在 2024 年的工作中，本人积极出席相关会议，慎重审议董事会和 董事会专门委员会的各项议案，发挥了独立董事的独立性和专业性作用，维护了 公司和股东尤其是中小股东的利益。 现将 2024 年度本人履行独立董事职责的工作情况报告如下： 一、独立董事基本情况 本人宋希亮，1965 年出生，管理学博士,山东财经大学会计学院会计学教授, 硕士生导师, 曾任山东圣阳电源股份有限公司、威海华东数控股份有限公司、普 联软件股份有限公司、青岛森麒麟轮胎股份有限公司、山东省中鲁远洋渔业股份 有限公司、山东明仁福瑞达制药股份有限公司独立董事,现任宁波微科 ...

现金管理进展公告 证券代码：300653 证券简称：正海生物 公告编号：2025-004 烟台正海生物科技股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2024 年 3 月 31 日，公司召开第三届董事会第十五次会议及第三届监事会第 十三次会议审议通过了《关于使用自有资金进行现金管理的议案》，同意公司使 用总额度不超过人民币 70,000 万元闲置自有资金进行现金管理。使用期限自公 司股东大会审议通过之日起 12 个月内。公司在 2024 年 4 月 22 日召开的 2023 年年度股东大会审议通过了上述议案。本次购买理财产品的额度和期限均在审批 范围内，无需另行提交董事会、股东大会审议。 现将公司近期使用闲置自有资金进行现金管理的相关事宜公告如下： | 受托方 | 产品名称 | 产品 | 金额 | 起始日 | 到期日 | 预计年化 | | --- | --- | --- | --- | --- | --- | --- | | | | 类型 | （万元） | | | 收益率 | | 浦发银行烟台 | ...